BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28208810)

  • 21. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
    Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
    Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
    Liao YM; Wang YH; Hung JT; Lin YJ; Huang YL; Liao GS; Hsu YL; Wu JC; Yu AL
    Breast Cancer Res; 2021 Jan; 23(1):5. PubMed ID: 33413566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
    Li J; Davidson D; Martins Souza C; Zhong MC; Wu N; Park M; Muller WJ; Veillette A
    Mol Cell Biol; 2015 Dec; 35(23):4069-82. PubMed ID: 26391955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition.
    Chen SC; Kung ML; Hu TH; Chen HY; Wu JC; Kuo HM; Tsai HE; Lin YW; Wen ZH; Liu JK; Yeh MH; Tai MH
    J Pathol; 2012 Oct; 228(2):158-69. PubMed ID: 22247069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
    Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
    Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.
    Kwak T; Drews-Elger K; Ergonul A; Miller PC; Braley A; Hwang GH; Zhao D; Besser A; Yamamoto Y; Yamamoto H; El-Ashry D; Slingerland JM; Lippman ME; Hudson BI
    Oncogene; 2017 Mar; 36(11):1559-1572. PubMed ID: 27669433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer.
    Feng J; Xu G; Liu J; Zhang N; Li L; Ji J; Zhang J; Zhang L; Wang G; Wang X; Tan J; Huang B; Lu J; Zhang Y
    Breast Cancer Res Treat; 2016 Oct; 159(3):443-56. PubMed ID: 27572339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells.
    Castellana B; Aasen T; Moreno-Bueno G; Dunn SE; Ramón y Cajal S
    Oncotarget; 2015 Nov; 6(35):38239-56. PubMed ID: 26512918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
    Sausgruber N; Coissieux MM; Britschgi A; Wyckoff J; Aceto N; Leroy C; Stadler MB; Voshol H; Bonenfant D; Bentires-Alj M
    Oncogene; 2015 Apr; 34(17):2272-8. PubMed ID: 24931162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells.
    Lee Y; Jung WH; Koo JS
    Breast Cancer Res Treat; 2015 Sep; 153(2):323-35. PubMed ID: 26285644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
    Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
    Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear factor I-C regulates E-cadherin via control of KLF4 in breast cancer.
    Lee HK; Lee DS; Park JC
    BMC Cancer; 2015 Mar; 15():113. PubMed ID: 25879941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression.
    Zhang J; Liang Q; Lei Y; Yao M; Li L; Gao X; Feng J; Zhang Y; Gao H; Liu DX; Lu J; Huang B
    Cancer Res; 2012 Sep; 72(17):4597-608. PubMed ID: 22787120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SHPS-1/SIRP1alpha contributes to interleukin-6 signalling.
    Sobota RM; Müller PJ; Khouri C; Ullrich A; Poli V; Noguchi T; Heinrich PC; Schaper F
    Cell Signal; 2008 Jul; 20(7):1385-91. PubMed ID: 18450421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functions of Shp2 in cancer.
    Zhang J; Zhang F; Niu R
    J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
    Chen H; Libring S; Ruddraraju KV; Miao J; Solorio L; Zhang ZY; Wendt MK
    Oncogene; 2020 Dec; 39(49):7166-7180. PubMed ID: 33033382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells.
    Yu JM; Sun W; Hua F; Xie J; Lin H; Zhou DD; Hu ZW
    Cancer Lett; 2015 Sep; 365(2):190-200. PubMed ID: 26049022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
    Li J; Kang Y; Wei L; Liu W; Tian Y; Chen B; Lin X; Li Y; Feng GS; Lu Z
    PLoS One; 2014; 9(7):e102847. PubMed ID: 25048202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.